Skip to content

US · OPRX · MEDICAL - HEALTHCARE INFORMATION SERVICES

OptimizeRx Corp. (OPRX) intrinsic value and stock valuation

$6.70as of 2026-11-21 · Mkt cap 132.86M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OptimizeRx Corp. DCF and intrinsic value

InvestorsCraft values OPRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OPRX’s statements →

OptimizeRx Corp. Graham Number

Graham Number: $6.56d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Waltham, MA 02453 optimizerx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$109.4M+20.4% 5y CAGRd
20112025
Net income
$5.13M
20112025
Free cash flow
$18.7M
20112025
Total equity
$128.3M+20.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$109.4M$92.1M$71.5M$62.5M$61.3M
Operating income$12.1M-$-13.71M-$-26.4M-$-12.29M$360K
Net income$5.13M-$-20.11M-$-17.57M-$-11.44M$380K
EPSd$270K-$-1.1M-$-1.03M-$-643.42K$21.5K
Operating cash flow$18.7M$4.89M-$-7.24M$10.7M$730K
Capital expenditure-$-60K-$-110K-$-870K-$-240K-$-490K
Free cash flow$18.7M$4.78M-$-8.11M$10.4M$240K
Total assets$176.9M$171.2M$183.4M$134.7M$141M
Total debt$26.1M$33.2M$36.8M$230K$330K
Net debt$2.74M$19.8M$23M-$-17.97M-$-84.35M
Total equity$128.3M$117M$126.6M$126.1M$131.4M
Cash and short-term investments$23.4M$13.4M$13.9M$74.1M$84.7M
Income statement
20252024202320222021
Revenue$109.4M$92.1M$71.5M$62.5M$61.3M
Cost of revenue$40.2M$32.8M$28.6M$23.5M$25.7M
Gross profit$69.3M$59.4M$42.9M$39M$35.6M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$50.2M$61.3M$58M$49.2M$33.2M
Other expenses$6.96M$11.8M$11.3M$2.02M$2.09M
Operating expenses$57.2M$73.1M$69.3M$51.3M$35.3M
Cost and expenses$97.4M$105.8M$97.9M$74.7M$60.9M
Interest income$350K$330K$2.19M$850K$20K
Interest expense$5.29M$6.16M$1.45M$0.00$0.00
Depreciation and amortization$4.33M$4.33M$2.4M$2.02M$1.97M
Ebitda$16.6M-$-8.9M-$-21.31M-$-9.42M$2.34M
Operating income$12.1M-$-13.71M-$-26.4M-$-12.29M$360K
Total other income/expenses, net-$-5.11M-$-5.68M$1.24M$850K$20K
Income before tax$6.95M-$-19.39M-$-25.16M-$-11.44M$380K
Income tax expense$1.82M$720K-$-7.6M$0.00$0.00
Net income$5.13M-$-20.11M-$-17.57M-$-11.44M$380K
Weighted average shares outstanding$18.6M$18.3M$17.1M$17.8M$17.2M
Weighted average diluted shares outstanding$19M$18.3M$17.1M$17.8M$17.7M
Balance sheet
20252024202320222021
Cash and short-term investments$23.4M$13.4M$13.9M$74.1M$84.7M
Net receivables$38.5M$38.2M$37.3M$22.2M$24.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$64.7M$54M$54.3M$98.6M$115.1M
Property, plant and equipment, net$510K$520K$720K$370K$470K
Goodwill and intangible assets$111.7M$116.4M$127.8M$35.7M$25.4M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$112.2M$117.2M$129M$36.1M$25.9M
Total assets$176.9M$171.2M$183.4M$134.7M$141M
Accounts payable$1.64M$2.16M$2.23M$1.55M$610K
Short-term debt$4.45M$2.17M$2.22M$90K$90K
Deferred revenue$500K$470K$170K$160K$1.39M
Total current liabilities$21.3M$18.7M$17.9M$8.4M$9.37M
Long-term debt$21.7M$31M$34.6M$140K$240K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$27.4M$35.5M$38.9M$140K$240K
Capital lease obligations$430K$380K$590K$230K$330K
Total liabilities$48.6M$54.2M$56.8M$8.54M$9.61M
Common stock$20K$20K$20K$20K$20K
Retained earnings-$-79.24M-$-84.37M-$-64.26M-$-46.69M-$-35.25M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$128.3M$117M$126.6M$126.1M$131.4M
Total investments$0.00$0.00$0.00$55.9M$0.00
Total debt$26.1M$33.2M$36.8M$230K$330K
Net debt$2.74M$19.8M$23M-$-17.97M-$-84.35M
Cash flow statement
20252024202320222021
Net income$5.13M-$-20.11M-$-17.57M-$-11.44M$380K
Depreciation and amortization$4.33M$4.33M$2.4M$2.02M$1.97M
Stock-based compensation$6.96M$11.5M$13.7M$15.8M$5.49M
Change in working capital$820K$920K-$-15.55M$3.96M-$-7.19M
Accounts receivable$460K-$-2.17M-$-8.71M$2.28M-$-6.99M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-520K-$-70K$200K$560K-$-600K
Net cash provided by operating activities$18.7M$4.89M-$-7.24M$10.7M$730K
Investments in property, plant and equipment-$-60K-$-110K-$-90K-$-80K-$-100K
Acquisitions, net$0.00$0.00-$-80.41M-$-2M$0.00
Net cash used for investing activities$70K-$-450K-$-25.34M-$-58.18M-$-490K
Common stock issued$350K$0.00$0.00$0.00$70.7M
Common stock repurchased$0.00-$-910K-$-7.52M-$-20.02M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-8.8M-$-4.91M$28.2M-$-18.95M$73.9M
Net change in cash$9.98M-$-470K-$-4.36M-$-66.47M$74.2M
Cash at end of period$23.4M$13.4M$13.9M$18.2M$84.7M
Operating cash flow$18.7M$4.89M-$-7.24M$10.7M$730K
Capital expenditure-$-60K-$-110K-$-870K-$-240K-$-490K
Free cash flow$18.7M$4.78M-$-8.11M$10.4M$240K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OptimizeRx Corp.

        OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

        CEO
        Stephen L. Silvestro
        Employees
        133
        Beta
        1.08

        Explore

        Frequently asked questions

        What is the intrinsic value of OptimizeRx Corp. (OPRX)?

        OptimizeRx Corp. (OPRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OPRX undervalued?

        OPRX trades at a price of $6.70 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.